istock-839222794-nicoelnino
NicoElnino / iStockphoto.com
21 January 2019Big Pharma

Novartis enters AI partnership with Oxford University

Novartis and the University of Oxford’s Big Data Institute (BDI) have joined forces to use artificial intelligence (AI) for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
9 September 2019   Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.
Big Pharma
3 October 2019   Novartis has teamed with Microsoft to launch a new artificial intelligence innovation lab, which it says has the potential to “transform” and “reimagine” medicine.
Americas
30 January 2020   Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.

More on this story

Big Pharma
9 September 2019   Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.
Big Pharma
3 October 2019   Novartis has teamed with Microsoft to launch a new artificial intelligence innovation lab, which it says has the potential to “transform” and “reimagine” medicine.
Americas
30 January 2020   Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.

More on this story

Big Pharma
9 September 2019   Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.
Big Pharma
3 October 2019   Novartis has teamed with Microsoft to launch a new artificial intelligence innovation lab, which it says has the potential to “transform” and “reimagine” medicine.
Americas
30 January 2020   Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.